The radiopharmaceutical landscape in 2026 is defined by the commercial maturity of beta emitters and the rapid clinical ascent of alpha therapies. In the strategic evaluation of Actinium-225 vs Lutetium-177,…
The commercial viability of radioligand therapy is intrinsically tied to one of the most unforgiving logistical networks in the healthcare industry. Unlike traditional biologics that can be physically stockpiled in…
The clinical pipeline for radiopharmaceuticals is undergoing a radical evolution. While the first wave of commercial success relied heavily on beta-emitting isotopes, researchers and biotech innovators are increasingly pivoting toward…